Comment on Pegylated Liposomal Doxorubicin Plus Docetaxel in Metastatic Breast Cancer

被引：3
|
作者：
Smith, Thomas J. [1 ]
Hillner, Bruce E.
机构：
[1] Virginia Commonwealth Univ, Massey Canc Ctr, Div Hematol Oncol, Richmond, VA 23284 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 08期
关键词：
COST-EFFECTIVENESS; TAXANE TREATMENT; PHASE-III; ANTHRACYCLINE; CAPECITABINE; COMBINATION; MONOTHERAPY; THERAPY;
D O I：
10.1200/JCO.2009.26.8243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E128 / E128
页数：1
相关论文
共 50 条
  • [41] Pegylated liposomal doxorubicin (Caelyx®) in metastatic breast cancer:: A community-based observation study
    Salzberg, Marc
    Thuerlimann, Beat
    Hasler, Ursula
    Delmore, Geoffrey
    von Rohr, Albert
    Thuerlimann, Annatina
    Ruhstaller, Thomas
    Stopatschinskaja, Shanna
    von Moos, Roger
    [J]. ONCOLOGY, 2007, 72 (3-4) : 147 - 151
  • [42] Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer
    Chang, Amy E.
    Wu, Qian V.
    Jenkins, Isaac C.
    Specht, Jennifer M.
    Gadi, Vijayakrishna K.
    Gralow, Julie R.
    Salazar, Lupe G.
    Kurland, Brenda F.
    Linden, Hannah M.
    [J]. CLINICAL BREAST CANCER, 2018, 18 (01) : E143 - E149
  • [43] Phase II evaluation of liposomal doxorubicin combined with docetaxel in patients with metastatic breast cancer.
    Uldrick, T
    Crew, K
    Tiersten, A
    Braffman, L
    Blozie, K
    Hershman, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 104S - 104S
  • [44] Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)
    Li, Ruoyang
    Tian, Fuguo
    Qi, Yixin
    Ma, Li
    Zhou, Tao
    Li, Yuntao
    Hui, Tianli
    Zhang, Lina
    Wang, Shuo
    Song, Zhenchuan
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [45] Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)
    Ruoyang Li
    Fuguo Tian
    Yixin Qi
    Li Ma
    Tao Zhou
    Yuntao Li
    Tianli Hui
    Lina Zhang
    Shuo Wang
    Zhenchuan Song
    [J]. Scientific Reports, 9
  • [46] PHARMACOECONOMIC ANALYSIS OF PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS DOXORUBICIN IN PATIENTS WITH METASTATIC BREAST CANCER AT HIGH RISK OF CARDIAC EVENTS
    Krysanov, I
    Tiapkina, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A731 - A732
  • [47] Non-pegylated Liposomal Doxorubicin (Myocet ®) Plus Docetaxel (Taxotere ®) (MYTAX), as First-line Chemotherapy (CHT), in Metastatic Breast Cancer (MBC): Results of a Phase II Study
    Imperatori, L.
    Lippe, P.
    Trapuzzano, C.
    Laici, G.
    Cappelletti, C.
    Tamburrano, T.
    Mattioli, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S353 - S353
  • [48] A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
    Laber, Damian A.
    Eatrides, Jennifer
    Jaglal, Michael V.
    Haider, Mintallah
    Visweshwar, Nathan
    Patel, Ankita
    [J]. MEDICAL ONCOLOGY, 2020, 37 (10)
  • [49] A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
    Damian A. Laber
    Jennifer Eatrides
    Michael V. Jaglal
    Mintallah Haider
    Nathan Visweshwar
    Ankita Patel
    [J]. Medical Oncology, 2020, 37
  • [50] Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
    Lyass, O
    Uziely, B
    Ben-Yosef, R
    Tzemach, D
    Heshing, NI
    Lotem, M
    Brufman, G
    Gabizon, A
    [J]. CANCER, 2000, 89 (05) : 1037 - 1047
12345